浙江奥翔药业股份有限公司

Core Points - Zhejiang Aoxiang Pharmaceutical Co., Ltd. has revised its internal management systems and company charter to enhance governance and compliance with relevant laws and regulations [1][12][16] - The company plans to hold a Q3 2025 performance briefing on November 11, 2025, to discuss its financial results and address investor inquiries [5][6][7] - The company has announced a temporary shareholders' meeting scheduled for November 18, 2025, to discuss various proposals, including the cancellation of the supervisory board and amendments to the company charter [32][33][34] Group 1: Company Governance and Internal Management - The company has revised its charter and internal management systems to improve governance and ensure compliance with the Company Law and Securities Law of the People's Republic of China [1][12] - The revised internal management systems were approved by the board and will take effect after shareholder approval [1][12] Group 2: Q3 Performance Briefing - The Q3 2025 performance briefing will take place on November 11, 2025, from 15:00 to 16:00 at the Shanghai Stock Exchange Roadshow Center [5][6] - Investors can submit questions from November 4 to November 10, 2025, and the company will address common concerns during the briefing [5][6][7] Group 3: Shareholders' Meeting - The first temporary shareholders' meeting of 2025 is set for November 18, 2025, with both on-site and online voting options available [32][33][34] - The meeting will discuss the cancellation of the supervisory board and the revision of the company charter, among other matters [32][33][34]